Chronic Lymphocytic Leukemia Therapeutics Market Size Share Analysis

Major Players in the global chronic lymphocytic leukemia therapeutics market 2022-2029 include GlaxoSmithKline Plc, AbbVie Inc., Biogen Idec, AstraZeneca, Genentech Inc., MorphoSys AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Portola Pharmaceuticals, Inc, Celgene Corporation

GlaxoSmithKline Plc

• GlaxoSmithKline is a science-led global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer.
• It is the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life
• GlaxoSmithKline pharmaceuticals business has a broad portfolio of innovative and established medicines in HIV, respiratory, immuno-inflammation and oncology 
• GlaxoSmithKline in early 2020, started a two-year programme to prepare GSK for separation into two new, exciting companies - a new GSK in Biopharma and a new world leader in Consumer Healthcare. The company remains on track to separate it in 2022

AbbVie Inc.

• AbbVie is a publicly-traded biopharmaceutical company in the United States. It began as a spin-off from Abbott Laboratories
• The company now operates in several key therapeutic areas, including immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology, as well as products and services from its Allergan Aesthetics portfolio.
• The company engages in the development and sale of pharmaceutical products.
• AbbVie takes pride in developing new treatments for chronic conditions and life-threatening illnesses, and its drugs include cancer treatment Imbruvica and Humira, an immunosuppressant used to treat arthritis and Crohn's disease
• In 2020, AbbVie acquired Allergan, an Irrish drug manufacturer.

Biogen Idec

• Biogen Inc. is a multinational biotechnology company based in the United States. 
• The company specializes in the discovery, development, and delivery of therapies to patients worldwide for the treatment of neurological diseases.
• The company’s portfolio includes Rituxan and Zevalin, both of which treat B-cell non-lymphoma, Hodgkin's are among the company's approved drugs. Biogen Idec sells Amevive, a psoriasis treatment, and Avonex, the best-selling treatment for relapsing multiple sclerosis. 
• The company has facilities and offices in San Diego and around the world. Biogen Idec is present throughout Europe, as well as in Canada, Japan, and Australia.

Genentech Inc.

• Genentech Inc. is a biotechnology company based in the United States that became a subsidiary of Roche in 2009.
• The company is dedicated to pioneering science to discover and develop medicines for people suffering from serious and life-threatening diseases. 
• In the United States, Roche and Genentech merged their pharmaceutical operations. The Genentech campus in South San Francisco is now the headquarters for Roche's pharmaceutical operations in the United States. Genentech Research and Early Development is a separate entity within Roche.
• Roche Holding Ltd. owns 66 percent of Genentech but allows it to operate independently. Genentech discovers, develops, manufactures, and sells human pharmaceuticals to meet critical medical needs.
• F. Hoffmann-La Roche Ltd is the parent company of genetech Inc.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com